Emtricitabine/tenofovir disoproxil fumarate is named as an intervention in 4 current clinical trials in our USA and UK registers. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Gilead Sciences. The most-studied condition is Pre-Exposure Prophylaxis of HIV Infection.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
NCT07473778 · HIV Infections
|
Observational | Recruiting | Gilead Sciences | USA |
|
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
NCT06101329 · ClinicalTrials.gov ↗ · Pre-Exposure Prophylaxis of HIV Infection
|
Phase 2 | Active, closed | Gilead Sciences | USA |
|
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)
NCT06101342 · Pre-Exposure Prophylaxis of HIV Infection
|
Phase 2 | Active, closed | Gilead Sciences | USA |
|
Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)
NCT06513312 · Pre-Exposure Prophylaxis of HIV Infection
|
Phase 2 | Active, closed | Gilead Sciences | UK |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Gilead Sciences | 4 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 1 |
| Clinical trials in UK | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our USA and UK registers name Emtricitabine/tenofovir disoproxil fumarate as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 4 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Gilead Sciences. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Emtricitabine/tenofovir disoproxil fumarate works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Emtricitabine/tenofovir disoproxil fumarate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Emtricitabine/tenofovir disoproxil fumarate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.